Tradewinds Capital Management’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Tradewinds Capital Management’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-36	Closed	–	–	759
2016 Q4	$0	Hold	36	–	–	﹤0.01%	732
2016 Q3	$0	Buy	+36	New	+$542	﹤0.01%	713

Other funds holding MBVX

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRD

Dennis R. Delaney $282M AUM 16.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tradewinds Capital Management's MBVX Position: Q1 2017 in Review

Tradewinds Capital Management sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q1 2017, closing a stake of 36 shares.

Tradewinds Capital Management first reported a position in MBVX in Q3 2016 and held it in 2 quarters. The position peaked at $0 in Q4 2016. 8 funds tracked by Wall St. Rank hold MBVX as of Q1 2017.

Tradewinds Capital Management reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q1 2017 after selling out during the quarter.
Tradewinds Capital Management sold 36 MABVAX THERAPEUTICS HLDGS INC shares in Q1 2017.
Tradewinds Capital Management first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2016 and held it in 2 quarters.
Tradewinds Capital Management's MABVAX THERAPEUTICS HLDGS INC position peaked at $0 in Q4 2016.
8 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q1 2017.

Based on Tradewinds Capital Management's 13F filing for Q1 2017, filed 3 May 2017.